热门资讯> 正文
Lexeo Therapeutics GAAP每股收益为-0.64美元
2024-08-12 21:10
- Lexeo Therapeutics press release (NASDAQ:LXEO): Q2 GAAP EPS of -$0.64.
- As of June 30, 2024, cash and cash equivalents were $175.0 million,
-
More on Lexeo Therapeutics
- Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
- Lexeo stock drops 24% amid Friedreich Ataxia study results
- Historical earnings data for Lexeo Therapeutics
- Financial information for Lexeo Therapeutics
风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。